中文

Process
Upstream Process Development
Focus on quality
・Quality by Design
・Risk Management
Competitive development time
・From cell pool to 15L process in 4 months;
・Upstream process lock from a Top 1 cell poolcan be achieved in as fast as 2.5 months;
Unique cell culture platforms
・Orbital shaken cell culture system (10-2500L);
・Stirred-tank Reactor (3L to 2000L);
Advanced upstream cellculture platforms
・Fed-batch culture;
・Intensive fed-batch culture;
・Perfusion culture.

Titer up to ~39 g/L.

Perfusion culture obtains higher
cell fineness and longer culture time.

CBoost™‌
High Inoculation Density and High Expression Levels
Based on optimized inoculation strategies, volumetric productivity is significantly enhanced.
Highly Platformized
Applicable to multiple cell lines and product types, facilitating process transfer and scale-up.
Robust Process with Broad Applicability
The process remains stable across differentscales and culture modes, supporting flexible manufacturing strategies.
CBoost Advanced
Fed-batch Perfusion Culture
High cell viability is maintained through precise nutrient feeding and metabolite control.
Extended Culture Duration
Long-term production is achieved at sustained high cell density, increasing yield per batch.
Maximize Production Efficiency
Comprehensive optimization of process parameters to fully leverage cellular expression potential.
Orbital Shaker Bioreactor Platform
Advantages
Shorter mixing time
Lower shear force
Fewer air bubbles
Easy scale-up
Issues in Stirred-TankReactor (STR) Culture
・Low Viability, Low Viable Cell Density
・Protein Aggregation, Low Expression Titer
Switch to OrbitalShaker Bioreactor
・Both cell growth and expression titerhave been improved
Our Core Competencies
End-to-End Bioprocess Development
Bioprocess development services ready for tech-transfer and scale-up topilot and GMP production
CHO-Rise® Medium development platform
Self developed formula, localized manufacture, significantly reduced costs
Flexible culture platform
Stirred bioreactor, orbital shaken bioreactor

Next-Generation

Upgraded Formula

30% Enhancement VS Competitors

Serum-Free

Chemically Defined

Perfectly Compatible with Canton's Self-Developed CHOZen® Cells and CANVector® Systems

Excellent Cell Growth and Viability Performance
Powered by Cantonbio CHO-Rise Plus® , CHO-K1 maintains robust growthand near-100 % viability throughout 14-day fed-batch, outperforming commercial alternatives

Cell Growth

High Expression Level, Covering Multiple Modalities
With Cantonbio CHO-RisePlus® medium, mAbs, bsAbs, recombinant and hard-to-express proteins all achieve high titers above industrybenchmarks and competitors.

CHO Rise® Medium demonstrates excellent expression levels across multiple modalities

Using Cantonbio CHO-Rise Plus medium for antibody production significantly increases fucosylation and reduces high-mannose compared with competitors (left), or, for fucose-removal projects, employs a specialty cell line to eliminate fucose and lower high-mannose (right).

Glycosylation Analysis

Cantonbio CHO-Rise Plus® delivers higher product purity and lower fragments/aggregates than competitor media.

Product Purity

Cantonbio CHO-Rise Plus® yields antibodies with more consistent charge heterogeneity than competitor media.

Charge Variants

Trust from Customers
"With Canton's media, our CHO titers readily exceed gram levels and production costs drop sharply."
Process Director XX Biotech
"Canton's media delivers fast, stable target-protein expression, accelerating our lab projects."
University of HongKong Lab
Product Features
Animal-derived component-free
Chemically defined
Does not contain L-Glutamine (L-Gln) or phenol red
Applicable to: High-efficiencyrecombinant protein expression of cell lines including CHO-K1,CHOZN, CHO-S, and CHO-DG44 under fed-batch and high-density fed-batch processes
Name Catalog Number Type Specification
CHO-Rise @ BM01 (Basal Medium) CB-MCBO1L-1L Liquid 1L
CB-MCB01P-1kg Powder 10L/50L
CHO-Rise R BM02 (Basal Medium) CB-MCB02L-1L Liquid 1L
CB-MCB02P-1kg Powder 10L/50L
CHO-Rise R FM01 (Main Feed) CB-MCFO1L-0.5L Liquid 0.5L
CB-MCF01P-1kg Powder 5L/50L
CHO-Rise R FM02 (Main Feed) CB-MCFO2L-0.5L Liquid 0.5L
CB-MCF02P-1kg Powder 5L/50L
CHO-Rise @ FS01 (Supplemental Feed) CB-MCS01L-0.2L Liquid 0.2L
CB-MCS01P-0.2kg Powder 1L/10L
Downstream Process Development
Competitive Development Timeline
Scalable downstream process completed within 2–4 months
Gram‑scale protein for research purposes delivered within 2 weeks
Diversified Chromatography Process Platform
Purification of conventional and special‑configuration antibodies
Tagged / Tag‑free protein purification
Bispecific antibody purification
Advanced Purification Processes
Two‑step antibody purification process
Non‑affinity antibody purification process
High‑throughput membrane chromatography process
Continuous chromatography process
Customized Purification Process Platform

Three‑step IgG platform

Purity > 98%

HCP residual < 20 ppm

Recovery rate ~80%

Two‑step IgG platform

Purity > 98%

HCP
residual < 20ppm

Recovery rate ~ 80%

Non‑affinity IgG platform

Purity > 98%

HCP residual < 50ppm

Recovery rate ~70%

IgG membrane chromatography platform

Purity > 99%

HCP residual < 10ppm

Recovery rate ~70%

IgM platform

Purity > 98%

Host cell protein
residual < 100ppm

Recovery rate ~55%

Bispecific antibody platform

Purity > 97%

HCP residual < 30ppm

Recovery rate ~60%

Recombinant protein platform

Purity > 97%

HCP residual < 50ppm

Recovery rate ~50%

Fusion protein platform

Purity > 97%

HCP residual < 30ppm

Recovery rate ~60%

Formulation and Process Development
Diverse Formulation Dosage Forms
Liquid, lyophilized, semi‑solid, eye drops, inhalation, nasal spray
Experience in Developing Formulations for Various Molecules
Conventional antibodies, special-configuration antibodies, bispecific antibodies, complex recombinant proteins, exosomes
Primary Packaging
Vials, PFS, BFS, nasal spray pumps, inhalation pumps
High‑Throughput Stability Analysis Capability
By measuring Tagg value, stability of 384 samples can be predicted within 1 hour

Formulation development, container‑closure screening,
formulation process development, in‑use stability study

Video